Synthaverse
SVE.WASynthaverse is a modern, dynamically developing Polish biotech that leverages its expertise and proprietary technologies to develop and deliver solutions shaping global health. The company has a diversified portfolio of commercial and development-stage products, primarily in immunotherapy, and supports its innovation through close cooperation with scientific centers. Its ambition is to push the boundaries of medicine while maintaining a strong focus on contract manufacturing and laboratory reagents. Led by CEO Mieczysław Starkowicz, the company combines decades of experience with a forward-looking approach to research and production.
SVE.WA · Stock Price
Historical price data
AI Company Overview
Synthaverse is a modern, dynamically developing Polish biotech that leverages its expertise and proprietary technologies to develop and deliver solutions shaping global health. The company has a diversified portfolio of commercial and development-stage products, primarily in immunotherapy, and supports its innovation through close cooperation with scientific centers. Its ambition is to push the boundaries of medicine while maintaining a strong focus on contract manufacturing and laboratory reagents. Led by CEO Mieczysław Starkowicz, the company combines decades of experience with a forward-looking approach to research and production.
Technology Platform
Proprietary technologies for developing immunotherapies and biological medical products, with expertise in both active (vaccines) and passive (immunoglobulin) immunotherapy approaches.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Synthaverse competes with large global players like Merck in BCG immunotherapy and Takeda/CSL in immunoglobulins, as well as numerous firms in the probiotics market. Its differentiation is based on proprietary technologies, a focus on specific immunotherapy niches, and an integrated business model combining proprietary products with contract manufacturing services.